News

 

 

Funding: New Awards

New Awards

Elizabeth Barry, PhD
Member, Cancer Epidemiology and Chemoprevention Research Program at Norris Cotton Cancer Center, and Research Assistant Professor of Community and Family Medicine at Dartmouth Medical School

  • DHHS NIH
    Genetic variants influencing response to vitamin D in colorectal chemoprevention

Duane Compton, PhD (co-investigator)
Member, Cancer Mechanisms Research Program at Norris Cotton Cancer Center, and Professor of Biochemistry at Dartmouth Medical School

Ethan Dmitrovsky, MD (co-investigator)
Co-Director, Cancer Epidemiology and Chemoprevention Research Program at Norris Cotton Cancer Center, and Professor of Pharmacology and Toxicology at Dartmouth Medical School

Yolanda Sanchez, PhD (co-investigator)
Member, Molecular Therapeutics Research Program at Norris Cotton Cancer Center, and Associate Professor of Pharmacology and Toxicology at Dartmouth Medical School

  • Samuel Waxman Cancer Research Foundation
    Overcoming oncogene addiction by targeting genome instability

James Moseley, PhD
Member, Cancer Mechanisms Research Program at Norris Cotton Cancer Center, and Assistant Professor of Biochemistry at Dartmouth Medical School

  • The Pew Charitable Trusts
    The role of cell geometry in triggering mitotic entry

Tracy Onega, PhD
Member, Cancer Control Research Program at Norris Cotton Cancer Center, and Assistant Professor of Community and Family Medicine at Dartmouth Medical School

  • National Cancer Institute
    5-year R01 entitled: Effectiveness of preoperative MRI in breast cancer surgery and outcomes
New Clinical Trials

Marc Ernstoff, MD
Member, Immunology and Cancer Immunotherapy Research Program at Norris Cotton Cancer Center, and Professor of Medicine at Dartmouth Medical School

  • NCI/Sub University of Pittsburgh (Prometheus Laboratories Inc)
    A Randomized Phase II Study of Sequential Biotherapy with Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study 
  • Bristol Myers Squibb
    A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects with Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 
  • AVEO Pharmaceuticals, Inc.
    A Phase 2 and Biomarker Study of Tivozanib in Subjects with Advanced Renal Cell Carcinoma